Key Differences Between PSURs and DSURs in Pharmacovigilance

Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs) are both crucial tools in pharmacovigilance. Although they serve a similar purpose—ongoing evaluation of drug safety—they apply to different stages of a medicinal product’s lifecycle and are governed by distinct guidelines. Understanding the differences between PSURs and DSURs is essential for professionals involved in regulatory affairs, clinical development, and drug safety monitoring.

What is a PSUR?

A PSUR is a report that provides a comprehensive evaluation of the benefit-risk profile of a medicinal product during the post-marketing phase. Governed by ICH E2C(R2), it includes cumulative safety data and is submitted periodically to health authorities such as the EMA and CDSCO (India).

• Purpose: Monitor the ongoing safety of marketed products
• Audience: Regulatory authorities, risk management teams, medical reviewers
• Key output: Benefit-risk assessment, safety signals, and labeling recommendations

What is a DSUR?

A DSUR, on the other hand, is submitted during the clinical development phase and focuses on investigational drugs. It follows ICH E2F guidelines and emphasizes the safety of trial participants.

• Purpose: Monitor safety of investigational drugs during clinical trials
• Audience: Clinical trial sponsors, investigators, regulatory agencies
• Key output: Assessment of safety data from ongoing trials

Side-by-Side Comparison Table

Use Cases: When Do You Submit a PSUR vs DSUR?

PSURs are submitted for authorized, marketed drugs. For example, a company marketing an antihypertensive in the EU must submit a PSUR according to the EURD list schedule.

DSURs are required for drugs in clinical trials. If a new oncology product is undergoing Phase 2 trials across multiple regions, a harmonized DSUR submission is mandatory to regulators including USFDA.

Overlap Between PSUR and DSUR

In some situations—such as ongoing expanded access programs or simultaneous development and marketing—both PSUR and DSUR may be required. Sponsors must:

• Ensure consistent safety messages across both reports
• Coordinate data lock points (DLPs) and submission dates
• Cross-reference overlapping safety signals and risk management actions

Content Differences in Detail

PSUR Content Highlights:

• Cumulative AE data from spontaneous reports
• Post-marketing studies and literature surveillance
• Benefit-risk reevaluation and safety signals
• Labeling changes and market withdrawals

DSUR Content Highlights:

• Investigator Brochure (IB) updates
• Protocol amendments and changes in study design
• Unblinded data summaries (if needed)
• Clinical trial subject disposition and safety outcomes

To maintain SOP compliance, organizations often refer to structured formats from Pharma SOP templates for DSUR and PSUR content standardization.

Global Regulatory Submissions and Harmonization

Some regulatory authorities allow the use of harmonized formats:

• EMA allows PBRER format to replace PSUR
• Japan accepts ICH DSUR format with minor modifications
• CDSCO India and TGA Australia align with ICH guidelines
• FDA permits submission of PSUR content within the Annual Report or PADER

Role of Automation in Managing Both Reports

Modern pharmacovigilance platforms now allow:

• Shared signal detection modules for PSUR and DSUR
• Automated data extraction and tabulation
• Workflow tracking and compliance dashboards
• Combined template-driven authoring environments

For example, tools featured at Pharma Validation support validated report generation processes to meet multiple regional requirements efficiently.

Conclusion

While PSURs and DSURs both serve the common goal of ensuring drug safety, their application, structure, and regulatory expectations differ significantly. PSURs provide a post-marketing perspective, while DSURs focus on clinical development safety. It’s essential for pharma professionals to understand these differences to ensure timely, compliant, and high-quality submissions that meet both regulatory and ethical standards.

Using a combination of internal SOPs, validated templates, and automated tools, organizations can manage PSUR and DSUR requirements more efficiently—supporting both ongoing patient safety and product lifecycle management.